Treatment of tenosynovial giant tumors with colony‐stimulating factor 1 receptor kinase inhibitors: When to start? When to stop? When to restart?

Long‐term treatment of nonresectable tenosynovial giant cell tumor with pexidartinib is feasible and provides long‐term control and symptomatic improvement, with acceptable tolerance. Treatment interruption is possible, and one half of patients remain without progression after interruption. Among those who relapse, pexidartinib is again active, although not all patients need to resume treatment.